載入...
Weekly osimertinib dosing prevents EGFR mutant tumor cells destined to home mouse lungs
The recently conducted ADAURA trial concludes daily dosing of adjuvant osimertinib, a third-generation EGFR tyrosine kinase inhibitor (TKI), improves disease-free survival with stage IB/II/IIIA EGFR -mutated non-small cell lung cancer patients in comparison to placebo. We have developed a preclinica...
Na minha lista:
| 發表在: | Transl Oncol |
|---|---|
| Main Authors: | , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Neoplasia Press
2021
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8236545/ https://ncbi.nlm.nih.gov/pubmed/33993094 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.tranon.2021.101111 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|